vs

Side-by-side financial comparison of IRIDEX CORP (IRIX) and SuperCom Ltd (SPCB). Click either name above to swap in a different company.

IRIDEX CORP is the larger business by last-quarter revenue ($14.7M vs $14.2M, roughly 1.0× SuperCom Ltd). On growth, SuperCom Ltd posted the faster year-over-year revenue change (-1.5% vs -69.7%).

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

Super.com is a technology company headquartered in San Francisco and co-founded by Hussein Fazal and Henry Shi. The company provides financial services, including reward programs and travel bookings.

IRIX vs SPCB — Head-to-Head

Bigger by revenue
IRIX
IRIX
1.0× larger
IRIX
$14.7M
$14.2M
SPCB
Growing faster (revenue YoY)
SPCB
SPCB
+68.3% gap
SPCB
-1.5%
-69.7%
IRIX

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
IRIX
IRIX
SPCB
SPCB
Revenue
$14.7M
$14.2M
Net Profit
$5.3M
Gross Margin
37.2%
61.2%
Operating Margin
16.3%
Net Margin
37.5%
Revenue YoY
-69.7%
-1.5%
Net Profit YoY
79.5%
EPS (diluted)
$1.32

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRIX
IRIX
SPCB
SPCB
Q4 25
$14.7M
Q3 25
$12.5M
Q2 25
$13.6M
$14.2M
Q1 25
$11.9M
Q4 24
$12.7M
Q3 24
$11.6M
Q2 24
$12.6M
$14.4M
Q1 24
$11.8M
Net Profit
IRIX
IRIX
SPCB
SPCB
Q4 25
Q3 25
$-1.6M
Q2 25
$-994.0K
$5.3M
Q1 25
$-1.7M
Q4 24
$-834.0K
Q3 24
$-1.9M
Q2 24
$-2.7M
$3.0M
Q1 24
$-3.5M
Gross Margin
IRIX
IRIX
SPCB
SPCB
Q4 25
37.2%
Q3 25
32.1%
Q2 25
34.5%
61.2%
Q1 25
42.5%
Q4 24
44.0%
Q3 24
37.3%
Q2 24
40.7%
52.3%
Q1 24
37.9%
Operating Margin
IRIX
IRIX
SPCB
SPCB
Q4 25
Q3 25
-11.3%
Q2 25
-6.9%
16.3%
Q1 25
-1.7%
Q4 24
-3.9%
Q3 24
-16.1%
Q2 24
-20.9%
7.7%
Q1 24
-28.0%
Net Margin
IRIX
IRIX
SPCB
SPCB
Q4 25
Q3 25
-12.6%
Q2 25
-7.3%
37.5%
Q1 25
-14.2%
Q4 24
-6.6%
Q3 24
-16.7%
Q2 24
-21.2%
20.6%
Q1 24
-29.5%
EPS (diluted)
IRIX
IRIX
SPCB
SPCB
Q4 25
Q3 25
$-0.09
Q2 25
$-0.06
$1.32
Q1 25
$-0.10
Q4 24
$-0.05
Q3 24
$-0.12
Q2 24
$-0.16
$1.19
Q1 24
$-0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRIX
IRIX
SPCB
SPCB
Cash + ST InvestmentsLiquidity on hand
$6.0M
$15.0M
Total DebtLower is stronger
$23.6M
Stockholders' EquityBook value
$37.3M
Total Assets
$29.2M
$65.5M
Debt / EquityLower = less leverage
0.63×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRIX
IRIX
SPCB
SPCB
Q4 25
$6.0M
Q3 25
$5.6M
Q2 25
$6.8M
$15.0M
Q1 25
$7.2M
Q4 24
$2.4M
Q3 24
$3.9M
Q2 24
$4.1M
$5.7M
Q1 24
$5.4M
Total Debt
IRIX
IRIX
SPCB
SPCB
Q4 25
Q3 25
Q2 25
$23.6M
Q1 25
Q4 24
$1.0M
Q3 24
$1.4M
Q2 24
$29.2M
Q1 24
Stockholders' Equity
IRIX
IRIX
SPCB
SPCB
Q4 25
Q3 25
$4.7M
Q2 25
$6.1M
$37.3M
Q1 25
$852.0K
Q4 24
$2.1M
Q3 24
$2.6M
Q2 24
$4.2M
$13.8M
Q1 24
$6.5M
Total Assets
IRIX
IRIX
SPCB
SPCB
Q4 25
$29.2M
Q3 25
$28.4M
Q2 25
$31.6M
$65.5M
Q1 25
$34.2M
Q4 24
$29.1M
Q3 24
$30.2M
Q2 24
$31.2M
$49.6M
Q1 24
$34.1M
Debt / Equity
IRIX
IRIX
SPCB
SPCB
Q4 25
Q3 25
Q2 25
0.63×
Q1 25
Q4 24
0.48×
Q3 24
0.53×
Q2 24
2.11×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRIX
IRIX
SPCB
SPCB
Operating Cash FlowLast quarter
$-2.2M
Free Cash FlowOCF − Capex
$-3.6M
FCF MarginFCF / Revenue
-25.3%
Capex IntensityCapex / Revenue
10.0%
Cash ConversionOCF / Net Profit
-0.41×
TTM Free Cash FlowTrailing 4 quarters
$-14.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRIX
IRIX
SPCB
SPCB
Q4 25
Q3 25
$-1.2M
Q2 25
$-397.0K
$-2.2M
Q1 25
$-1.1M
Q4 24
$-1.2M
Q3 24
$-3.1M
Q2 24
$-1.3M
$-950.0K
Q1 24
$-1.6M
Free Cash Flow
IRIX
IRIX
SPCB
SPCB
Q4 25
Q3 25
$-1.2M
Q2 25
$-410.0K
$-3.6M
Q1 25
$-1.2M
Q4 24
$-1.2M
Q3 24
$-3.1M
Q2 24
$-1.6M
Q1 24
$-1.7M
FCF Margin
IRIX
IRIX
SPCB
SPCB
Q4 25
Q3 25
-9.4%
Q2 25
-3.0%
-25.3%
Q1 25
-9.8%
Q4 24
-9.8%
Q3 24
-26.5%
Q2 24
-10.8%
Q1 24
-14.0%
Capex Intensity
IRIX
IRIX
SPCB
SPCB
Q4 25
Q3 25
0.1%
Q2 25
0.1%
10.0%
Q1 25
0.1%
Q4 24
0.1%
Q3 24
0.0%
Q2 24
0.0%
4.2%
Q1 24
0.0%
Cash Conversion
IRIX
IRIX
SPCB
SPCB
Q4 25
Q3 25
Q2 25
-0.41×
Q1 25
Q4 24
Q3 24
Q2 24
-0.32×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons